MedTrace Logo

Efficacy and Safety of Nicotine-Qbeta Vaccine in Smokers

NCT00369616 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 341

Last updated 2010-11-15

No results posted yet for this study

Summary

The purpose of this study is to help smokers quitting by vaccinating them with CYT002-NicQb. Upon vaccination, the smoker will generate antibodies directed against free nicotine. The antibodies will bind nicotine and prevent its passage into the brain. The successfully vaccinated smoker will have no reward effect after smoking, thus braking the vicious circle of nicotine addiction.

Conditions

  • Smokers

Interventions

BIOLOGICAL

CYT002-NicQb

Sponsors & Collaborators

  • Cytos Biotechnology AG

    lead INDUSTRY

Principal Investigators

  • Jacques Cornuz, Prof. · Department of Medicine; University Hospital Lausanne, Switzeland

  • Thomas Cerny, Prof. · Department of Medicine, Kantonsspital St. Gallen, Switzerland

  • Felix Jungi, MD · Department of Medicine, Kantonsspital St. Gallen, Switzerland

  • Karl Klingler, MD · Lung Center Hirslanden, Zuerich, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2005-03-31
Completion
2005-10-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00369616 on ClinicalTrials.gov